# Engineered Immune Effectors Against Cervical Cancer

> **NCT03362619** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Shenzhen Geno-Immune Medical Institute** · enrollment: 20 (estimated)

## Conditions studied

- Cervical Cancer

## Interventions

- **BIOLOGICAL:** CC-EIEs

## Key facts

- **NCT ID:** NCT03362619
- **Lead sponsor:** Shenzhen Geno-Immune Medical Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-11-15
- **Primary completion:** 2019-01-31
- **Final completion:** 2020-12
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2019-09-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03362619

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03362619, "Engineered Immune Effectors Against Cervical Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03362619. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*